CLEW, a developer of software using artificial intelligence (AI), said it has received an emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) for a tool to help providers determine which COIVD-19 patients are at increased risk for respiratory failure or hemodynamic instability, according to a press release from the company.
CLEW said the AI-based algorithms are machine-learning models trained to identify respiratory failure and or hemodynamic instability hours in advance. The models were trained on nearly 100,000 patients in the ICUs and were developed to be used in both local ICUs and TeleICUs.
The streamlined at-a-glance web application is designed for near real-time access to patient data and data elements and provides a specific deterioration probability for each patient.
